XTR006

DRUG3 trials

Sponsors

Sinotau Pharmaceutical Group

Conditions

Alzheimer DiseaseNeurofibrillary Tangle

Phase 1

A Study to Evaluate XTR006 in Chinese Volunteers

CompletedNCT06151795

Sinotau Pharmaceutical GroupAlzheimer Disease

Start: 2023-06-12End: 2024-01-10Updated: 2024-05-03

Phase 3

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

RecruitingNCT07115238

Sinotau Pharmaceutical GroupAlzheimer Disease, Neurofibrillary Tangle

Start: 2024-11-20End: 2026-06-30Target: 354Updated: 2025-08-11

Unknown Phase

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

CompletedNCT06151808

Sinotau Pharmaceutical GroupAlzheimer Disease

Start: 2022-09-01End: 2024-01-10Updated: 2024-05-03